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[571 ABSTRACT 
The present invention provides a method and apparatus for 
separating a blood sample having a volume of up to about 20 
milliliters into cellular and acellular fractions. The apparatus 
includes a housing divided by a fibrous filter into a blood 
sample collection chamber having a volume of at least about 
1 milliliter and a serum sample collection chamber. The 
fibrous filter has a pore size of less than about 3 microns, and 
is coated with a mixture including between about 1-40 
wtlvol % mannitol and between about 0.1-15 wtlvol % of 
plasma fraction protein (or an animal or vegetable equiva- 
lent thereof). The coating causes the cellular fraction to be 
trapped by the small pores, leaving the cellular fraction 
intact on the fibrous filter while the acellular fraction passes 
through the filter for collection in unaltered form from the 
serum sample collection chamber. 
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METHOD AND APPARATUS FOR THE 
COLLECTION, STORAGE, AND REAL TIME 
ANALYSIS OF BLOOD AND OTHER BODILY 
FLUIDS 
RELATED APPLICATION 
is important in order to avoid contamination of the acellular 
fraction with components from the cellular fraction. For 
example, the separation process, itself, can cause the cells in 
the sample to lyse and release the intracellular content into 
s the sample, thereby contaminating the sample. 
Methods for separating clinically useful volumes of blood 
generally require the blood to be collected, transferred into 
a glass or Plastic vial, and then centrifuged at high speed for 
a period of time. Centrifugation causes the cellular or solid 
10 fraction of the sample to collect at the bottom of the vial and 
the acellular supernatant plasma or serum to collect at the 
top of the vial. The supernatant then can be decanted and 
analyzed. Sometimes, the vial is provided with a medium 
density inert gel which-due to its specific gravity- 
under a NASA ‘Ontract and is subject to the 15 substantially isolates the cellular from the acellular fraction 
when centrifuged, permitting the components to be frozen 
Centrifugation and subsequent refrigeration of samples is 
sufficient to preserve the integrity of a sample of blood or 
2o other bodily fluid for a sufficient period of time in most 
mis application is a continuation-in-part of u,s, ser, N ~ ,  
08/605,300 filed Jan. 26, 1996, now U.S. Pat. No. 5,665,238 
which is a continuation of u,s, ser, N ~ ,  081247,187 filed 
May 19, 1994, now abandoned. 
ORIGIN OF THE INVENTION 
The invention described herein was made in the perfor- 
provisions of Section 305 of the National Aeronautics and 
U.S.C. 2457). 
Of 
Space Act Of 1958, Public Law 85-568 (72 Stat. 435; 42 and stored together, 
FIELD OF THE INVENTION 
The present invention provides a simp1e, inexpensive 
(Or 
simultaneously Or subse- 
cases. However, the process is cumbersome and expensive 
because it requires the blood or other sample either to be 
that the sample be refrigerated and transferred to a separate 
of time is required to obtain the results of the analysis. Time 
method and apparatus for passively separating 
solid) and acellular fractions of clinically useful volumes of 
quently 
collected in a location having all of the proper equipment, or 
fluids for One Or more 25 laboratory for further processing. Also, a substantial amount 
may be critical to the life or health of the patient; therefore, 
a more rapid, less expensive, less cumbersome method is 
One of the primary means used to diagnose the state of a needed to analyze samples of blood and/or other bodily 
person’s health is to analyze the person’s blood or other 30 fluids. 
bodily fluids for the presence or absence of “analytes” Some methods exist for separating and analyzing very 
indicative of the person’s health. An “analyte” is any sub- small volumes of blood or other bodily fluids in situ, 
stance contained in a bodily fluid for which either knowl- ~ ~ ~ i ~ ~ l l ~ ,  these involve exposing the blood or other 
edge of the presence or concentration is desired for clinical sample to a porous membrane or a porous mat of glass, fiber, 
Or laboratory Purposes, Or for which the substance itself is 35 or a polymer of plastic, protein, or carbohydrate, which traps 
retained and used for Some other analytical Or Pharmaco- the cellular components (or solids) but permits the plasma to 
logical Purpose. AnalYtes such as hormones, salts, enzymes, flow through onto a paper or plastic strip where the plasma 
ketones, glucose, drugs, infectious agents, etc., indicate is reacted immediately with analytical reagents. 
fluids, for 
said 
analytes, and for prolonged preservation Of said analytes. 
BACKGROUND OF THE INVENTION 
whether the person has contracted an infection 
whether the glands 
Unfortunately, current methods and devices used for in 
Other Organs are func- 40 situ analyses produce only a very small volume of serum or 
plasma which can be used only to measure one or a limited tioning effectively. 
Certain bodily fluids, such as urine, saliva, semen, etc. can number of small analytes, such as glucose, electrolytes, and 
be obtained non-invasively and analysis of such fluids can pH. The sample of blood must be small-typically less than 
provide information about the state of a person’s health. 45 100 microliters, Because the entire sample is reacted imme- 
Some analytes will be found only in certain bodily fluids, diately with the testing reagent(s), the entire sample is 
such as cerebrospinal fluid. However, the bodily fluid that disposed of after it has been used for this limited purpose, 
typically gives the most complete Picture of a Person’s None of the sample can be stored or used for any other 
health is whole blood. testing. 
The in situ separation devices in current use often either 
composed of both solid and liquid components. For fractions, or they separate the serum into subfractions, 
example, whole blood is composed of two fractions. One thereby altering the biochemistry of the serum. Also, the 
fraction is a ‘‘cellular” fraction, which includes the various type of analyses that can be performed using such devices 
types of blood cells and any other relatively ‘‘Solid’’ matter 55 typically is a one stage procedure. The analyte is mixed with 
found in the blood. The other fraction is an “acellular” one or a number of reagents simultaneously to produce a 
fraction which consists of Plasma Or serum. Most of the color change or chemical reaction. Because these devices 
“analytes” of interest are contained in the acellular fraction. lack a supportive matrix and a path through which the 
In order to obtain the most accurate analysis of the blood, sample can pass before further analysis, they cannot be used 
it is important to separate the analytes from the cellular 60 to perform a multiple stage analysis capable of measuring 
fraction of the blood relatively quickly after the sample is complex molecules, such as hormones, enzymes, antibodies, 
drawn. Otherwise, the quantity and or quality of various or viral particles. In addition, the accuracy of such analyses 
analytes in the blood may be altered by the cellular fraction, is impaired by the presence of hemoglobin, which is freed by 
e.g., by metabolism, release of intracellular content, and/or the hemolysis or rupture of red blood cells in the sample. 
simple dilution. The current methods used to test bodily fluids in situ also 
For similar reasons, the manner in which the cellular lack a convenient means for prolonged storage of viable 
fraction is separated from the acellular fraction of the blood samples. Currently, samples of bodily fluids must be refrig- 
One difficulty e ~ o u n t e r e d  in analyzing many bodily 50 
fluids, such as whole blood, is that the “fluid” actually is do not separate the sample into cellular and acellular 
65 
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erated at or below -20" C. in order to maintain the bio- 
chemical integrity of the sample. If the sample is to be tested 
for certain short lived or delicate analytes, preservatives 
and/or acids often must be added to preserve the integrity of 
the analytes. 
Some tests permit whole blood samples to be stored on 
blotting paper dried in air-for example, for neonatal pur- 
poses. However, these dried samples: can be used only to 
test qualitatively for a limited number of analytes; cannot be 
used for quantitative testing; and, only remain viable for 
testing for about two weeks. The short term viability for such 
dried samples largely results because the blood cells tend to 
rupture and contaminate the sample with intracellular con- 
tents during the drying process. The free hemoglobin 
released in the rehydration process also interferes with many 
colorimetric assays. 
Some analytes, such as insulin, can be preserved in a 
desiccated state by freeze drying the analyte under a 
vacuum. Unfortunately, a significant number of analytes that 
can be preserved in a desiccated state denature at some point 
during the process. Therefore, freeze drying of analytes is 
only of limited use to test for analytes that do not denature. 
An accurate, efficient process for in situ collection, 
separation, testing, and storage of bodily fluids, such as 
blood, which can be used for a broad spectrum of analytes 
would be highly desirable. 
SUMMARY OF THE INVENTION 
The present invention provides a method and apparatus 
for separating a blood sample having a volume of up to 
about 20 milliliters into cellular and acellular fractions 
comprising the steps o f  
providing a housing comprising at least one opening 
therethrough for receiving a blood sample; providing a 
fibrous filter comprising a first surface, substantially all 
of which fluidly communicates with a blood sample in 
said blood sample collection chamber, a second surface 
abutting and fluidly communicating with said serum 
sample collection chamber, and an intermediate portion 
having a given height sandwiched between and in fluid 
communication with both said first and said second 
surfaces, wherein said fibrous filter has a pore size of 
about 3 microns or less and is coated with a mixture 
comprising between about 1-40% mannitol and 
between about 0.1-15% of a protein selected from the 
group consisting of a plasma fraction protein, animal 
equivalents of a plasma fraction protein, and vegetable 
equivalents of a plasma fraction protein; and, separat- 
ing said blood sample into cellular and acellular frac- 
tions by filtering said blood sample from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is an exploded perspective view of the apparatus 
FIG. 2 is a compilation of the results from Examples 1 and 
of the invention. 
2 
DETAILED DESCRIPTION OF THE 
INVENTION 
For ease in description, the method and apparatus of the 
present invention will be explained with reference to the 
separation and analysis of whole blood. However, the 
4 
present invention is not limited to whole blood. The inven- 
tion also may be used to separate and test other bodily fluids 
in situ, whether of human or animal origin. Such bodily 
fluids include, but are not limited to, blood, urine, saliva, 
s tears, menstrual fluid, ascitic fluid, peritoneal fluid, joint 
fluid, cerebrospinal fluid, semen, transudate, or exudate. 
Knowing the particular body fluid and the type of analyte to 
be tested, a person of skill in the art can determine the 
appropriate parameters in light of the following description. 
Referring to FIG. 1, a preferred embodiment of the 
apparatus 10 of the present invention comprises tubing 12 or 
other means for transferring a bodily fluid of interest into a 
collection chamber 14 formed by an opening in a substan- 
tially flat or planar shell 16. The shell 16, which is preferably 
15 made of a relatively inert clear plastic, has flanges 20 at its 
outer edges which extend toward a filter card 22. The surface 
area of the shell 16 adjacent to the filter card 22 is slightly 
larger than the surface area of the filter card 22, so that, once 
the apparatus 10 is assembled, the flanges 20 house the filter 
20 card 22 substantially abutting the opening in the shell 16. 
The sides of the collection chamber 14 comprise the sides of 
the opening in the shell 16 and the bottom of the chamber 14 
comprises the abutting filter card 22. The filter card 22 
should be positioned so that the blood or other bodily fluid 
2s that is deposited in the collection chamber 14 covers sub- 
stantially the entire surface of the filter card 22 to infiltrate 
substantially the entire filter card 22. 
The filter card 22 may be composed of any suitable 
fibrous material having a large surface area, an appropriate 
30 density, and an appropriate average pore size. In a preferred 
embodiment, the filter card 22 is made from glass fiber, 
which has a larger surface area than most fibers, permitting 
the use of a smaller volume of fibrous material to separate 
the components of the fluid. For whole blood, a desirable 
3s average pore size is less than about 3 u, preferably about 1 
u, and a desirable density, if the filter card is made from glass 
fiber, is a basis weight of about 465 gm/m2. Lighter mate- 
rials generally are preferred. A preferred embodiment uses 
#32 Glass Fiber Filter, Catalog #08090, obtained from 
40 Schleicher and Schuell (Keene, New Hampshire). Other 
suitable materials for the filter card 22 include, but are not 
limited to, cellulose fibers, natural organic fibers, semi 
synthetic fibers, synthetic fibers, and hydrophilic polymeric 
gels. 
The filter card 22 should be treated with a proteid 
carbohydrate mixture comprised of between about 1-40% 
wtivol carbohydrate mixed with 0.1-15% wtivol non- 
specific protein, preferably about 10%-20% wtivol carbo- 
hydrate and about 5 4 %  wtivol protein. Apreferred embodi- 
ment uses about 10% wtivol mannitol and about 6% wtivol 
albumin. 
Preferred carbohydrates include: monosaccharides, such 
as fructose, galactose, and glucose; disaccharides, such as 
5s mannitol, lactose, and sucrose; and, complex polymeric 
sugars, such as starch and glycogen. Preferred proteins 
include human plasma fractions and plasma fraction 
proteins, such as albumin, globulin, transport proteins, and 
animal and vegetable equivalents thereof The filter card 22 
60 preferably is treated with the proteinicarbohydrate mixture 
by dipping the filter card 22 in a solution of the proteid 
carbohydrate solution and then air drying the filter card 22. 
Treatment of the filter card 22 with the proteid 
carbohydrate mixture permits the separation of relatively 
65 large volumes of whole blood up to about 20 milliliters. The 
amount of blood that can be separated is limited only by the 
size of the apparatus 10. The relative proportion, absolute 
10 
4s 
so 
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amount, and composition of the carbohydrateiprotein mix- 
ture provides variable and optimal control of the separation 
process while preventing cell lysis. The speed, cleanliness, 
and efficiency of the separation process can be altered by: (a) 
changing the absolute concentration of carbohydrate and/or 
protein in the mixture; (b) applying positive or negative 
pressure to one side of the filter card 22; and/or (c) varying 
the relative size of pores in the filter card 22 and absorbent 
matrix 30. 
The “efficiency” of the process generally refers to the 
ability of the process to extract the largest percentage of 
available serum or acellular fluid contained in a particular 
sample. The apparatus and method of the present invention 
normally recovers approximately 80-100% of the serum in 
whole blood. The “cleanliness” of the process refers to how 
effectively the process screens the serum or fluid of cells 
and/or other solids. Generally, increasing the concentration 
of carbohydrate in the solution used to coat the filter card 22 
increases the efficiency and cleanliness of the separation but 
decreases the speed of the separation. Therefore, a higher 
concentration of carbohydrate, in the range of 10-20% 
wtivol, normally is preferred as long as the analytes to be 
tested will survive for about 30 minutes to about 1 hour. 
Some analytes are extremely delicate and/or have extremely 
short half lives. In order to test for such analytes, it may be 
necessary lower the concentration of carbohydrate some- 
what and accept a lower level of efficiency and cleanliness 
of the process. In some cases, a preserving agent may be 
added to to the sample before beginning the separation 
process in order to preserve such analytes. Another way to 
preserve some short lived analytes might be to include an 
antibody for the analyte on the absorbent matrix 30. The 
binding of the analyte to the specific antibody, itself, may 
preserve the analyte for further analysis. 
After passing through the filter card 22, the plasma 
fraction reaches a serum sample collection chamber. In the 
apparatus depicted in FIG. 1, the serum sample collection 
chamber contains an absorbent matrix 30, preferably posi- 
tioned in direct contact with the filter card 22. The absorbent 
matrix 30 preferably is made from a material having a 
relatively high “Klemm” factor, on the order of at least about 
15, preferably about 30-70. In a preferred embodiment, the 
absorbent matrix 30 is Plasma Card Grade 900, a cellulose 
filter having a Klemm factor of about 64, obtained from 
Schleicher & Schuell (Product #56630). Other suitable 
materials for the absorbent matrix 30 include, but are not 
limited to, sepharose gel, agar, and glass fiber matting. 
Where a vacuum will be used to separate the blood, the 
apparatus need not have an absorbent matrix. In a preferred 
embodiment (not depicted), a fibrous filter fits in a standard 
blood collection test tube, preferably in the form of a ‘‘sock” 
which separates the test tube into two sections-a blood 
sample collection chamber and a serum sample collection 
chamber. The test tube preferably has a built-in vacuum. An 
example of such a container is the VACUTAINERTM, a 
commercial product well known in the art. In this 
embodiment, the serum simply is collected in the serum 
sample collection chamber of the test tube for further 
processing. In order to provide sufficient force without 
damaging the fibrous filter, the vacuum preferably should be 
between about 10-70 cm of water, preferably about 20 cm 
of water. 
Referring back to FIG. 1, once the device is assembled the 
flanges 20 adhere to a back plate 24, preferably forming a 
substantially water tight seal around the filter card 22 and 
absorbent matrix 30 using any suitable means known in the 
art. Although a substantially water tight seal is preferred, the 
6 
invention does not require a tightly sealed filter in a pressure 
vessel, as do many other techniques. 
The tubing 12, or other means used to deposit the bodily 
fluid in the collection chamber 14, may be directly con- 
5 nected to a venous catheter or other access or collection port 
for blood or another bodily fluid. In this way, the fluid 
sample can be immediately deposited in the collection 
chamber 14 and analyzed substantially as it is collected. If 
the fluid is blood, direct transfer of the fluid to the collection 
10 chamber 14 obviates the need for anticoagulation. If tubing 
is used, the tubing 12 preferably is engaged with a plate 18 
which has a suitable adapter 26, such as a male Luer port. 
The transfer of such fluid into the collection chamber 14 can 
be aided, if desired, by aspiration with a syringe using an 
15 aspiration port 28 in the back plate 24. The aspiration port 
28 may have any suitable construction which is compatible 
with an aspiration syringe. For example, the port may be a 
female Luer port which extends away from the body of the 
apparatus 10. The aspiration port 28 preferably should be 
20 sealed using any known means capable of maintaining the 
water tight seal within the apparatus 10, but also permitting 
disruption of the seal if aspiration is desired. 
The separation process may be continued until the filter 
card 22 and/or the absorbent matrix 30 is filled. The blood 
25 or other bodily fluid passes through the filter card 22 by 
capillary action independent of gravity. The passive opera- 
tion of the apparatus 10 is advantageous because one of the 
contemplated uses for the invention is to collect, separate, 
and store blood or other bodily fluids during space flight in 
30 the absence of gravity. In addition, capillary action does not 
require a centrifuge or other cumbersome equipment to 
separate the bodily fluid. Compared to the glass or plastic 
vials and powered equipment required to separate bodily 
fluids by centrifuge, the apparatus 10 of the present inven- 
The absorbent matrix 30 preferably is supported in a 
frame 32 made of any suitable material, preferably a rela- 
tively inert clear plastic. The absorbent matrix 30 and the 
4o back plate 24 preferably are provided with pull-tabs 34. 
When the filtration process is complete, the pull-tabs 34 
permit the removal of the absorbent matrix 30 from the 
apparatus 10 without the need for direct contact which could 
contaminate the absorbent matrix 30. 
The absorbent matrix 30 and/or the filter card 22 may be 
impregnated with any number of suitable reagents to test for 
particular analytes, including well known reagents used to 
conduct specific antibody mediated assays, enzyme medi- 
ated assays, ligand mediated assays, and binding resins. As 
so already alluded to, the filter card 22 and/or the absorbent 
matrix 30 also may be impregnated with specific chemicals 
and/or antibod(ies) which will preserve delicate or short 
lived analytes for later extraction and analysis. Also, because 
the separation process can begin substantially simulta- 
55 neously with the collection of the bodily fluid, biochemical 
changes in the concentration and/or structure of analytes due 
to the presence of a cellular fraction are minimized or 
eliminated. For example, the cellular fraction is not available 
to consume glucose or other consumable analytes in the 
60 sample. The preservation of short lived and/or delicate 
analytes can be enhanced by prechilling the apparatus 10 
before use, and/or by transferring the apparatus 10 to a 
cooled environment as soon as possible during or after the 
separation process. 
The absorbent matrix 30 may be used and/or stored in a 
number of different ways. In a preferred embodiment, the 
absorbent matrix 30 is dried by subjecting the matrix to a 
35 tion is extremely portable. 
45 
65 
process. Compared to other available methods for storing 
such samples, the procedures required to preserve and store 
the absorbing matrix 30 in robust condition are simple, 
inexpensive, and portable. Storing bodily fluids on the 
absorbent matrix 30 can preserve a broad range of the 
analytes for clinical and research purposes for extended 
periods of at least days to weeks. In fact, some analytes 
which are very dificult to preserve by freezing have been 
preserved using the present invention. 
The use of a clear plastic shell 16, flanges 20, and back 
plate 24 will result in an additional advantage. The clear 
plastic will permit the filtration process to be observed. An 
end point for the process can be selected by choosing an 
acceptable time, determined partly by the design of the filter 
and the fluid being absorbed or by watching the area of 
discoloration of the absorbing matrix 30 through the back 
plate 24. Furthermore, the chemical testing reagent(s) can be 
impregnated onto either the absorbent matrix 30 or both the 
absorbent matrix 30 and/or the filter card 22 and then a color 
change, agglutination, or other process taking place on the 
absorbing matrix 30 can be observed through the clear 
plastic. In addition, the assay may be by direct fluoroscopy, 
spectroscopy, or thermal or electrical impedance. The latter 
will require the incorporation of appropriate electrodes into 
the plastic back plate. 
The apparatus 10 also can be adapted so that the results 
can be quantified. For example, a line of reagent “dots” may 
be engineered into the apparatus 10 so that the dots react to 
a specific concentration of analyte. After reaction, the dots 
may be compared to a scale which will quantify the results 
of such reaction. For example, the dots could be engineered 
to change color either absolutely or to an intensity that 
relates to the concentration of a particular analyte in the 
sample. The color of the dots after the reaction could be used 
to extrapolate the concentration of the analyte present in the 
whole blood, e.g., by comparison to a color scale which may 
be separate from or incorporated into the apparatus. 
If a series of dots is used, the reagent dots may be a 
specific chemical, such as a dye which changes color with 
pH or with the progress of an enzymatic process or cascade. 
For example, such a dot could be capable of detecting 
glucose through the action of the enzyme glucose oxidase. 
In a preferred embodiment, the “dot” detects an antibody 
mediated reaction which is specific to an analyte or a group 
of analytes. The antibody specifically binds to the analyte in 
the absorbing matrix and initiates a cascade of immu- 
nochemical reactions which produce an observable change. 
In another preferred embodiment of the device, the anti- 
body may be loosely bound in the filter card 22, itself, and 
therefore may pass through only with the passage of an 
analyte. Or, the antibody may be free in the filter card 22 or 
the collection chamber 14 such that the antibody is bound to 
a cell and does not pass through into the absorbent matrix 30 
5,866,007 
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flow of dry air which preferably should not exceed body 
temperature. Above about 40” C., enzymes and other deli- 
cate analytes on the absorbent matrix 30 tend to degrade. 
Once dried, the absorbent matrix can be placed in a con- 
tainer with a desiccant and an oxygen scavenger, such as an 5 reference to the following examples, 
activated cuprous compound, to reduce the water content 
EXAMPLE 1 and oxygen tension in the surrounding atmosphere. 
Preferably, the oxygen content of the air surrounding the 
sample should be maintained as close as possible to 0%. The was from 
sample also preferably should be isolated from light. a crewmember On the Space into both a vAcu- 
Othenvise, the sample may be stored in ambient conditions, lo TAINERTM and into the dried-blood collection device of the 
The addition of standard anti-peptidase chemicals, present invention. After insertion of an appropriate venous 
lytes whose concentrations may be altered in the drying TAINERTM adapter was attached and two Of 
whole blood were collected into two 5 ml VACUTAINERTM 
to initiate an identifying cascade. Any number of variations 
may be made to adapt test reagents for use in the present 
invention. 
clearly understood with The invention will be 
In this experiment 
antioxidants, and/or preservatives will protect certain ana- or butterfly procedures, the VACu- 
m1 
tubes. The venous line was occluded and the VACU- 
TAINERTM adapter removed. 
A blood collection device was attached to the cannula and 
inspected visually while it was filling. The operator was able 
to look through the clear casing of the blood collection 
2o device and observe the filling of the chamber with blood 
(produced by a water-sensitive dye) on the paper filter. After 
the chamber filled completely, the venous line again was 
occluded. The process was repeated until five blood- 
collection devices were filled. The cannula then was sealed 
The collection devices were fitted with Velcro tabs to 
anchor them to the working area and set aside for about one 
hour. After completion of the blood collection, the blood 
3o collection devices were inspected, and any droplets floating 
free in the chamber behind the absorbent material noted. If 
free fluid was present, the blood-collection device was 
moved to the drop until the drop was absorbed onto the 
absorbent material. When no free droplets were visible, the 
35 blood collection device was opened and the absorbent 
material (hereafter “card” or “cards”) containing the plasma 
was removed by pulling the tab. The casing of the blood- 
collection device was closed and the entire unit was dis- 
carded. The card then was transferred into the drying box 
4o where it slid down into grooves that supported and spaced 
the cards. The process was repeated for all 5 cards. A fan in 
the drying box was turned on and the cards were dried in a 
flow of room air for about 2 hours. At the end of the 2 hours, 
the fan was turned off and the dessicant and oxygen scav- 
45 enger was activated by removing the protective cover for 
these materials. The lid of the drying box was then closed 
and the cards were left in the box for storage. 
The two VACUTAINERTM samples were placed in a 
centrifuge and cells and plasma were separated according to 
established procedure. The VACUTAINERsTM then were 
placed in approximately -20” C. refrigeration and the time 
and date recorded. The entire unit was stowed for the 
remainder of the mission. 
After landing, the frozen serum was removed within 8 
5s hours and transferred to a refrigerated transfer canister. The 
dried cards in stowage also were retrieved and all samples 
returned for postflight analysis. Two days after landing, the 
serum was thawed, the dried cards were rehydrated, and the 
serum was extracted. The rehydration process involved 
60 removing the card from its plastic support frame, folding the 
card, placing the card inside a 10 ml tube, adding a set 
quantity of distilled water, rotating the tubes for 5 minutes 
and then extracting serum from the moistened paper by 
compressing the paper with the plunger of the syringe and 
The two sets of serum were analyzed simultaneously for 
the molecules shown in FIG. 2. The majority of analytes 
25 or removed. 
65 emptying the sample into the glass tube. 
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were measured in an automated CX 5 biochemistry unit 
obtained from Beckman Instruments (Brea, Calif.) using a 
combination of amperometric and photometric methods. 
Most of the hormones are analyzed by radioimmunoassay 
using commercially available methods. 
During the in-flight phase of the study, a ground-based 
control was run in which blood was drawn from two 
individuals using the same protocol and stored frozen or 
dried onto the card in the same way. The ground-based 
samples were subjected to conditions that were as similar to 
those of the in-flight samples as practical and were thawed 
or extracted and analyzed at the same time. 
Data from the in-flight samples and ground-based controls 
were analyzed for mean, standard deviation, and coefficient 
of variation. Results from in-flight samples stored frozen 
were compared to results from the dried stored samples. The 
results are shown in FIG. 2. 
The dried-blood-chemistry method provided accurate cor- 
relation to frozen samples taken in flight. In addition, the 
dried blood chemistry results show, in ground-based studies, 
a high correlation with samples of the same serum tested 
fresh. 
EXAMPLE 2 
Serum for this experiment (Protocol 2) was collected and 
pooled. Known quantities of certain analytes were added to 
artificially increase the concentrations to allow for some 
degradation before the experiment was begun and to give a 
broad representative group of all of the subcomponents of 
serum. The pooled serum with “spiked” concentrations of 
certain molecules, including melatonin, angiotensin, anti- 
diuretic hormone, and atrial naturetic factor, was filter 
sterilized, and loaded into 17 syringes two days before 
launch. Thirteen of the syringes contained the exact volume 
known to be held by the cards from ground-based studies, 
one contained about 3 mls of the correct volume, and five 
contained about 7 mis of the known volume. The remaining 
two 5 ml syringes served as controls, and were stored frozen 
after the fluid had been placed on the cards. 
Each syringe was capped and wrapped in Teflon tape to 
prevent leakage if broken. Each syringe was labeled with a 
code number and had a matching storage card similarly 
labeled. The syringes and cards were stored inside a semi- 
rigid “NOMEX’ (thick cloth) bag inside of a -20” C. 
freezer. A drying box identical to the box used in the first 
experiment also was flown. 
On a flight day early to midway through the mission, the 
syringes and cards were removed from their protective bags 
and each syringe was emptied in sequence onto its paired 
storage card. The emptied syringes were discarded. The two 
remaining syringes were stored frozen and the time and date 
were recorded. The cards were transferred to the “drying 
box” and the drying box fan turned on for about 2 hours. At 
the end of this period, the “rip-top’’ desiccant and oxygen 
scavenger container were opened and the drying box closed. 
The entire drying box, with cards inside, were placed inside 
a second plastic bag. The bag was sealed, and the entire unit 
was stowed in a middeck locker for the duration of the 
mission. After landing, the samples were handled as 
described in Example 1. 
The dried-blood-chemistry method provided accurate cor- 
relation to frozen samples taken in-flight. In addition, the 
dried blood chemistry results showed, in ground-based 
studies, a high correlation with samples of the same serum 
tested fresh. 
The invention has been described in connection with a 
particular embodiment. One of skill in the art will appreciate 
10 
that many modifications may be made to the embodiment 
described herein without departing from the spirit of the 
present invention. Accordingly, the embodiment described 
herein is illustrative only and is not intended to limit the 
s scope of the present invention. 
We claim: 
1. An apparatus for collecting and separating a blood 
a housing having at least one opening therethrough for 
a fibrous filter dividing said housing into: 
sample into cellular and acellular fractions comprising: 
10 receiving said blood sample; 
a blood sample collection chamber having a volume, 
said blood sample collection chamber being in fluid 
communication with said opening; and 
a serum sample collection chamber; 
said fibrous filter comprising a first surface, substantially 
all of which fluidly communicates with a blood sample 
in said blood sample collection chamber, a second 
surface abutting and fluidly communicating with said 
serum sample collection chamber, and an intermediate 
portion having a given height sandwiched between and 
in fluid communication with both said first and said 
second surfaces; 
wherein said blood sample is filtered from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber; and 
wherein said fibrous filter has a pore size of about 3 
microns or less and is coated with a mixture comprising 
in the range of from about 1 to about 40 wtivol % 
mannitol and in the range of from about 0.1 to about 15 
wtivol % of a protein selected from the group consist- 
ing of a plasma fraction protein, animal equivalents of 
a plasma fraction protein, and vegetable equivalents of 
a plasma fraction protein. 
2. The apparatus of claim 1 wherein said height of said 
3. The apparatus of claim 2 wherein said volume in the 
4. The apparatus of claim 2 wherein said coating on said 
fibrous filter comprises between about 10-20 wtivol % 
mannitol and between about 5-8 wtivol % of said protein. 
5 .  The apparatus of claim 2 wherein said protein is 
45 selected from the group consisting of albumin, gelatin, and 
globulin. 
6. The apparatus of claim 3 wherein said coating on said 
fibrous filter comprises between about 10-20 wtivol % 
mannitol and between about 5-8 wtivol % of said protein. 
7. The apparatus of claim 3 wherein said protein is 
selected from the group consisting of albumin, gelatin, and 
globulin. 
8. The apparatus of claim 6 wherein said protein is 
selected from the group consisting of albumin, gelatin, and 
9. The apparatus of claim 1 wherein said volume in the 
range of from about 1 to about 20 milliliters. 
10. The apparatus of claim 9 wherein said coating on said 
fibrous filter comprises between about 10-20 wtivol % 
60 mannitol and between about 5-8 wtivol % of said protein. 
11. The apparatus of claim 10 wherein said protein is 
albumin. 
12. The apparatus of claim 9 wherein said protein is 
albumin. 
13. The apparatus of claim 1 wherein said coating on said 
fibrous filter comprises between about 10-20 wtivol % 
mannitol and between about 5-8 wtivol % of said protein. 
2o 
25 
30 
35 
intermediate portion is about 1 millimeter or less. 
40 range of from about 1 to about 20 milliliters. 
SO 
ss globulin. 
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14. The apparatus of claim 13 wherein said protein is 
albumin. 
15. The apparatus of claim 1 wherein said protein is 
selected from the group consisting of albumin, gelatin, and 
globulin. 
16. The apparatus of claim 1 further comprising a separate 
absorbent matrix in said serum sample collection chamber, 
said absorbent matrix abutting said second surface and 
having a Klemm factor sufficiently high to passively draw a 
majority of said acellular fraction of said blood sample 
through said fibrous filter, leaving said cellular fraction on 
said fibrous filter and separating a majority of said acellular 
fraction into a removable acellular fraction. 
17. An apparatus for collecting and separating a blood 
sample into cellular and acellular fractions comprising: 
a housing having at least one opening therethrough for 
a fibrous filter dividing said housing into: 
receiving a blood sample; 
a blood sample collection chamber having a volume, 
said blood sample collection chamber being in fluid 
communication with said opening; and 
a serum sample collection chamber; 
said fibrous filter comprising a first surface, substantially 
all of which fluidly communicates with a blood sample 
in said blood sample collection chamber, a second 
surface abutting and fluidly communicating with said 
serum sample collection chamber, and an intermediate 
portion having a given height sandwiched between and 
in fluid communication with both said first and said 
second surfaces; 
wherein said blood sample is filtered from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber; and 
wherein said fibrous filter has a pore size below about 3 
microns and is coated with a mixture comprising in the 
range of from about 1 to about 40 wtivol % mannitol 
and in the range of from about 0.1 to about 15 wtivol 
% albumin. 
18. An apparatus for collecting and separating a blood 
sample of up to about 20 ml into cellular and acellular 
fractions comprising: 
a housing having at least one opening therethrough for 
a fibrous filter dividing said housing into: 
receiving said blood sample; 
a blood sample collection chamber having a volume of 
at least about 1 milliliter, said blood sample collec- 
tion chamber being in fluid communication with said 
opening; and 
a serum sample collection chamber; 
said fibrous filter comprising a first surface, substantially 
all of which fluidly communicates with a blood sample 
in said blood sample collection chamber, a second 
surface abutting and fluidly communicating with said 
serum sample collection chamber, and an intermediate 
portion having a height of about 1 millimeter or less 
sandwiched between and in fluid communication with 
both said first and said second surfaces; 
wherein said blood sample is filtered from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber; and 
wherein said fibrous filter has a pore size of about 3 
microns or less and is coated with a mixture comprising 
in the range of from about 1 to about 40 wtivol % 
12 
mannitol and in the range of from about 0.1 to about 15 
wtivol % albumin. 
19. An apparatus for collecting and separating a blood 
sample of up to about 20 ml into cellular and acellular 
a housing having at least one opening therethrough for 
a fibrous filter dividing said housing into: 
5 fractions comprising: 
receiving said blood sample; 
a blood sample collection chamber having a volume in 
the range of from about 1 to about 20 milliliters, said 
blood sample collection chamber being in fluid com- 
munication with said opening; and 
10 
a serum sample collection chamber; 
said fibrous filter comprising a first surface, substantially 
all of which fluidly communicates with a blood sample 
in said blood sample collection chamber, a second 
surface abutting and fluidly communicating with said 
serum sample collection chamber, and an intermediate 
portion having a height of about 1 millimeter or less 
sandwiched between and in fluid communication with 
both said first and said second surfaces; 
wherein said blood sample is filtered from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber; and 
wherein said fibrous filter has a pore size of about 3 
microns or less and is coated with a mixture comprising 
in the range of from about 1 to about 40 wtivol % 
mannitol and in the range of from about 0.1 to about 15 
20. An apparatus for collecting and separating a blood 
sample of up to about 20 ml into cellular and acellular 
fractions comprising: 
a housing having at least one opening therethrough for 
a fibrous filter dividing said housing into: 
15 
20 
25 
30 wtivol % albumin. 
35 receiving said blood sample; 
a blood sample collection chamber having a volume of 
at least about 1 milliliter, said blood sample collec- 
tion chamber being in fluid communication with said 
opening; and 40 
a serum sample collection chamber; 
said fibrous filter comprising a first surface, substantially 
all of which fluidly communicates with a blood sample 
in said blood sample collection chamber, a second 
surface abutting and fluidly communicating with said 
serum sample collection chamber, and an intermediate 
portion having a height of about 1 millimeter or less 
sandwiched between and in fluid communication with 
both said first and said second surfaces; 
wherein said blood sample is filtered from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber; and 
wherein said fibrous filter has a pore size of about 3 
microns or less and is coated with a mixture comprising 
in the range of from about 10 to about 20 wtivol % 
mannitol and in the range of from about 5 to about 8 
wtivol % albumin. 
21. An apparatus for collecting and separating a blood 
sample of up to about 20 ml into cellular and acellular 
fractions comprising: 
a housing having at least one opening therethrough for 
a fibrous filter dividing said housing into: 
45 
55 
60 
receiving said blood sample; 
a blood sample collection chamber having a volume in 
the range of from about 1 to about 20 milliliters, said 
65 
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blood sample collection chamber being in fluid com- 
munication with said opening; and 
a serum sample collection chamber; 
said fibrous filter comprising a first surface, substantially 
all of which fluidly communicates with a blood sample 
in said blood sample collection chamber, a second 
surface abutting and fluidly communicating with said 
serum sample collection chamber, and an intermediate 
portion having a height of about 1 millimeter or less 
sandwiched between and in fluid communication with 
both said first and said second surfaces; 
wherein said blood sample is filtered from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber; and 
wherein said fibrous filter has a pore size of about 3 
microns or less and is coated with a mixture comprising 
in the range of from about 10 to about 20 wtivol % 
mannitol and in the range of from about 5 to about 8 
wtivol % albumin. 
22. A method for separating a blood sample having a 
volume into cellular and acellular fractions comprising the 
steps o f  
providing a housing comprising at least one opening 
therethrough for receiving a blood sample; 
providing a fibrous filter comprising a first surface, sub- 
stantially all of which fluidly communicates with a 
14 
blood sample in said blood sample collection chamber, 
a second surface abutting and fluidly communicating 
with said serum sample collection chamber, and an 
intermediate portion having a given height sandwiched 
between and in fluid communication with both said first 
and said second surfaces, wherein said fibrous filter has 
a pore size of about 3 microns or less and is coated with 
a mixture comprising in the range of from about 1 to 
about 40 wtivol % mannitol and in the range of from 
about 0.1 to about 15 wtivol % of a protein selected 
from the group consisting of a plasma fraction protein, 
animal equivalents of a plasma fraction protein, and 
vegetable equivalents of a plasma fraction protein; and 
separating said blood sample into cellular and acellular 
fractions by filtering said blood sample from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum sample collection chamber. 
23. The method of claim 22 wherein said volume in the 
range of from about 1 to about 20 milliliters. 
albumin. 
albumin. 
24. The method of claim 23 wherein said protein is 
25. The method of claim 23 wherein said protein is 2s 
* * * * *  
